Half-year report · Q2
4568.TEDINET S100UN2H
Period2024-04-01 → 2024-09-30
Filed2024-11-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥882.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.60T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥726.3bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥186.9bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥95.1bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥192.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥237.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥102.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥146.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥200.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥97.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥146.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥97.0bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.30T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.46T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥2.65T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.67T | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.77T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.62T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.69T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.59T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.45T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.62T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.69T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.59T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥707.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥647.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥590.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥441.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥76.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥599.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥64.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥346.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥282.6bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥265.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥186.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥123.6bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥77.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥76.83 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥104.69 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥50.59 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥76.79 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥104.62 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥50.56 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 49.2% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 60.2% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 768
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment IFRS | CurrentYTDDuration | Original text (Japanese)当社グループは、「医薬事業」の単一セグメントであるため、報告セグメント別の記載は省略しております。 | |
| Notes business combinations condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes assets held for sale condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes bonds payable condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes share capital and other equity items condensed semi annual consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes dividends condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes other income condensed semi annual consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes cash flow information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes sale of subsidiaries condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes contingent liabilities condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes co development and co promotion condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |